NEWS

We inform you about the current business development of HAEMATO AG and about our investor relations activities.

HAEMATO AG acquires “M1 Aesthetics GmbH” from M1 Kliniken AG – Contribution of the company within the scope of a capital increase in kind of HAEMATO AG

HAEMATO AG acquires “M1 Aesthetics GmbH” from M1 Kliniken AG – Contribution of the company within the scope of a capital increase in kind of HAEMATO AG

Berlin, 15.12.2020 – M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contribution in kind. For this purpose, the Management Board of HAEMATO AG decided today with the approval of the Supervisory Board to increase the company’s share capital by EUR 2,467,201 to EUR 4,753,916 by issuing 2,467,201 new shares of HAEMATO AG through a capital increase against contribution in kind under exclusion of the subscription right of the shareholders by using the existing authorised capital. The new shares will be subscribed and taken over exclusively by M1 Kliniken AG. The transaction will be implemented with effect from 1.01.2021. After completion of the transaction, M1 Kliniken AG will hold a total of 75.8% of the share capital of HAEMATO AG.

read more
HAEMATO AG acquires “M1 Aesthetics GmbH” from M1 Kliniken AG – Contribution of the company within the scope of a capital increase in kind of HAEMATO AG

HAEMATO AG acquires “M1 Aesthetics GmbH” from M1 Kliniken AG – Contribution of the company within the scope of a capital increase in kind of HAEMATO AG

Berlin, 15.12.2020 – M1 Kliniken AG and HAEMATO AG today signed a contract for the acqui-sition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contri-bution in kind. For this purpose, the Management Board of HAEMATO AG decided today with the approval of the Supervisory Board to increase the company’s share capital by EUR 2,467,201 to EUR 4,753,916 by issuing 2,467,201 new shares of HAEMATO AG through a ca-pital increase against contribution in kind under exclusion of the subscription right of the shareholders by using the existing authorised capital. The new shares will be subscribed and taken over exclusively by M1 Kliniken AG. The transaction will be implemented with effect from 1.1.2021. After completion of the transaction, M1 Kliniken AG will hold a total of 75.8% of the share capital of HAEMATO AG.

read more

HAEMATO AG: Expansion of the board of directors: Strengthening the strategic and operative implementation of the product business in the Haemato Group Schönefeld, 30.11.2020 - The supervisory board of HAEMATO AG has appointed Mr. Patrick Brenske to the board of...

read more
Half Year Report 2020

Half Year Report 2020

In the first half of 2020, HAEMATO AG achieved an EBITDA of EUR 2,066 thousand. Sales amounted to EUR 115.8 million. In the first six months of the financial year 2020, HAEMATO AG, Berlin (ISIN: DE0006190705) achieved an IFRS group sales of EUR 115.8 million (previous...

read more

HAEMATO AG

HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany

Phone: +49-30 897 30 86 70
Telefax: +49-30 897 30 86 79
E-Mail: info@haemato.ag